Navigation Links
CXCR4: A new drug target in lung cancer
Date:4/29/2010

Geneva, 29 April 2010 -- Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.

CXCR4 is a receptor that is found on the surface of many different cell types in the body. It plays a role in immune system signaling between cells.

In cancer, evidence that CXCR4 is involved in the growth of tumors and their spreading throughout the body (metastasis) has been growing in recent years. For example, researchers have shown in studies in mice that blocking the action of CXCR4 inhibits metastasis. But its precise role in determining outcome and metastatic tendency, especially in lung cancer, is incompletely investigated.

Dr Gwyn Bebb and colleagues from the Tom Baker Cancer Centre in Calgary, Canada set out to explore whether patients whose tumors expressed high levels of the receptor had a worse prognosis than other lung cancer patients.

They studied tumor samples from 103 patients from the Glans-Look lung cancer database who were diagnosed with stage IV non-small-cell lung cancer (cancer which had already spread to other parts of the body) between 2003 and 2006. They found that 10.7% of the tumors over-expressed CXCR4. Those over-expressers had a significantly worse clinical outcome, with a median overall survival of 2.7 months, compared to 6.1 months among low-expressers.

If confirmed in an expanded series of 170 patients from the Glans-Look database, these results will suggest that new strategies to block CXCR4 should be tested in patients whose cancers over-express the molecule, the researchers say.

"I am quite excited about the possibility of using CXCR4 as a therapeutic target, but we need to learn more about its role in each specific malignancy," Dr Bebb said.

This possibility is especially promising because CXCR4 has been well studied in the context of HIV, where it is known to be a portal for the virus's entry into immune system cells. Drugs that block CXCR4 have already been developed for HIV/AIDS patients, and Dr Bebb's group thinks these drugs could quickly and easily be tested in the cancer setting.

"This is an exciting possibility," Dr Bebb said. "It seems very likely that a better understanding of the role of CXCR4 in lung cancer will lead to new treatment strategies and might allow us to meaningfully improve treatment for some lung cancer patients in the very near future."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Sundial Creations Announces the Debut of SheaMoisture Organic Hair Care Exclusively at Target
2. Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days
3. Global Summit on International Breast Health Targets Breast Health Improvements in Developing Countries, June 9-11, 2010, in Chicago
4. FDA Targets Safety Problems With Infusion Drug Pumps
5. Gene-Targeted Therapy Might Help Prevent Paralysis
6. Team finds promising new drug target for Alzheimers disease
7. Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building
8. New targeted therapy effective in treating advanced prostate cancer
9. Targeting the blood-brain barrier may delay progression of Alzheimers disease
10. Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients
11. New Study on Elder Care Marketing Reveals Fresh Insights in Targeting Aging Population
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner ... in Frederick, MD. Judy says, “I am passionate about sharing Reiki as a ... very difficult and challenging time.” , A Certified Medical Reiki™ Master trained by ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... In 2016 the World Health Organization declared the Zika virus ... Zika-related cases in the Americas within the next year. Lyme disease is one of ... skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses are ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... their communities, 16 more public health departments have been awarded national accreditation through ... 4.5 million people into the expanding network of communities across the nation whose ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The IoT (Internet ... WiFi connectivity are making a huge impact on businesses and individual consumers alike. ... the IoT will have a value anywhere from $4 trillion to $11 trillion dollars ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 23, 2017  Mirabilis Medical, a ... for non-invasive surgery, announced today CE Mark authorization ... of uterine fibroids throughout the European Union.  The ... from the US Food and Drug Administration to ... in the United States.  The Mirabilis System combines ...
(Date:3/24/2017)... GENEVA , March 24, 2017 ... revitalizes efforts to develop sutezolid as effective response to ... Day, TB Alliance and the Medicines Patent Pool (MPP) ... sutezolid, an antibiotic drug candidate which demonstrated encouraging results ... of sutezolid in combination with other TB drugs and ...
(Date:3/23/2017)... DUBLIN , Mar 23, 2017 Research ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... CAGR of around 6.9% over the next decade to reach approximately ... market estimates and forecasts for all the given segments on global ...
Breaking Medicine Technology: